What discharge plan is appropriate for a patient with rhabdomyolysis (creatine kinase decreasing from 18000 to 4900 U/L), nephrotic syndrome, heart failure with preserved ejection fraction, and peripheral arterial disease who is now producing yellow urine?

Discharge Plan for Rhabdomyolysis with Improving CK and HFpEF

This patient can be safely discharged on oral loop diuretics with careful attention to volume status, continuation of heart failure medications, close outpatient follow-up within 1 week, and strict avoidance of nephrotoxins. The production of yellow urine and declining CK (from 18,000 to 4,900 U/L) indicates adequate hydration and resolving rhabdomyolysis without acute kidney injury 1, 2.

Key Discharge Components

1. Diuretic Transition and Volume Management

Transition from IV to oral loop diuretics with careful dose titration 3, 4. For HFpEF patients, this is critical because:

• The patient must be euvolemic and hemodynamically stable for at least 24 hours before discharge 5
• Monitor for both supine and upright hypotension with medication changes 3
• Provide specific instructions for diuretic adjustment based on daily weights and symptoms 4

The challenge here is balancing adequate decongestion (essential for HFpEF) against the recovering kidney function from rhabdomyolysis. Recent evidence shows that small creatinine elevations (≤0.3 mg/dL) during diuresis should not prompt premature discontinuation if congestion persists 4.

2. Heart Failure Medication Optimization

Continue or initiate guideline-directed medical therapy (GDMT) for HFpEF before discharge 3, 4:

• ACE inhibitors or ARBs: Should be continued unless hemodynamic instability exists 3. For HFpEF with CKD, RASI use is associated with lower all-cause mortality (HR 0.58) 6
• Beta-blockers: Initiate only after volume optimization and discontinuation of IV diuretics 3
• MRAs: Consider if not contraindicated by potassium or renal function
• SGLT2 inhibitors: Emerging evidence supports use in HFpEF with renal benefits 7

The 2022 ACC/AHA guidelines emphasize that nearly half of HFrEF patients have no GDMT changes post-discharge despite suboptimal dosing 4. This same principle applies to HFpEF—optimize before discharge.

3. Rhabdomyolysis-Specific Considerations

Ensure complete resolution of myoglobinuria and stable renal function 1, 2:

• Yellow urine (vs. dark/tea-colored) indicates clearing of myoglobin
• CK trending down appropriately (4,900 from 18,000)
• Preserved renal function despite high CK is possible with adequate hydration 2

Critical nephrotoxin avoidance 8:

• NSAIDs: Absolute avoidance—particularly dangerous with diuretics and ACE inhibitors ("triple whammy") 8
• Educate patient to consult before taking any new medications, including over-the-counter drugs 8
• Avoid statins temporarily if rhabdomyolysis was drug-related 8

4. Monitoring Plan

Daily monitoring by patient 3, 4:

• Weight at same time each day
• Fluid intake/output awareness
• Symptoms of worsening HF (dyspnea, edema, orthopnea)
• Urine color (should remain yellow/clear)

Laboratory follow-up within 3-7 days 8:

• Serum creatinine, BUN, electrolytes (K+, Na+)
• CK level to confirm continued decline
• Consider cystatin C if creatinine interpretation unclear due to muscle loss 8

5. Follow-Up Appointments

Structured post-discharge care is essential 3, 5:

• Primary care within 1 week of discharge 5
• Cardiology within 2 weeks for HFpEF management 5
• Nephrology consultation if renal function worsens or CK plateaus

The 2009 ACC/AHA guidelines emphasize that post-discharge systems of care improve outcomes for HF patients 3. This is particularly important given the dual pathology.

6. Comprehensive Written Discharge Instructions

Provide detailed written instructions covering 3:

1. Diet: Sodium restriction (typically 2-3g/day for HFpEF), adequate hydration (2-2.5L/day unless fluid-restricted)
2. Medications: Specific doses, timing, and importance of adherence
3. Activity: Gradual return to activity; avoid strenuous exercise until CK normalizes
4. Warning signs: When to call doctor (weight gain >2-3 lbs in 1 day or 5 lbs in 1 week, worsening dyspnea, dark urine, severe muscle pain)
5. Follow-up appointments: Specific dates and times

7. PAD Considerations

For peripheral arterial disease management:

• Continue antiplatelet therapy if prescribed
• Emphasize smoking cessation if applicable
• Ensure adequate perfusion is not compromised by aggressive diuresis

Common Pitfalls to Avoid

1. Premature discharge: Don't discharge until stable on oral diuretics for ≥24 hours 5
2. Over-diuresis: Can worsen renal function and PAD symptoms
3. Under-treatment of HF: Failure to optimize GDMT before discharge leads to readmission 4
4. Inadequate nephrotoxin counseling: NSAIDs are ubiquitous and dangerous in this population 8
5. Poor follow-up planning: Lack of early outpatient visits increases readmission risk 5

Special Considerations for This Patient

The combination of resolving rhabdomyolysis, HFpEF, and PAD creates unique challenges:

• Volume status: Must achieve euvolemia without compromising peripheral perfusion or precipitating AKI recurrence
• Medication interactions: ACE inhibitors beneficial for HFpEF but require monitoring in recovering kidney function 6
• Risk stratification: Older patients with cardiovascular comorbidities have higher AKI risk in rhabdomyolysis 9

The production of yellow urine is a reassuring sign that myoglobinuria has resolved, but continued monitoring is essential as incomplete renal recovery occurs in many rhabdomyolysis patients 9.